European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tre
Go back to European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tre| INSMED (NASDAQ: INSM) | Delayed: 124.99 -1.3 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.29 | 52 Week High | $19.30 | |||
| Open | $124.78 | 52 Week Low | $9.02 | |||
| Day High | $127.42 | P/E | N/A | |||
| Day Low | $121.38 | EPS | $-1.69 | |||
| Volume | 361,176 | |||||
